INFU Stock Forecast 2025-2026
Distance to INFU Price Targets
INFU Price Momentum
10 Quality Stocks Worth Considering Now
Researching InfuSystem (INFU) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on INFU and similar high-potential opportunities.
Latest INFU Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, INFU has a bullish consensus with a median price target of $14.50 (ranging from $12.50 to $15.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $6.04, the median forecast implies a 140.1% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INFU Analyst Ratings
INFU Price Target Range
Latest INFU Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INFU.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 26, 2024 | B. Riley Securities | Buy | Initiates | $13.00 | |
| Apr 26, 2021 | Northland Capital Markets | James Terwilliger | Outperform | Initiates | $27.00 |
| Aug 31, 2020 | Craig-Hallum | Buy | Initiates | $0.00 |
InfuSystem Holdings Inc. (INFU) Competitors
The following stocks are similar to InfuSystem based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
InfuSystem Holdings Inc. (INFU) Financial Data
InfuSystem Holdings Inc. has a market capitalization of $126.90M with a P/E ratio of 54.9x. The company generates $134.86M in trailing twelve-month revenue with a 1.7% profit margin.
Revenue growth is +6.5% quarter-over-quarter, while maintaining an operating margin of +9.5% and return on equity of +4.3%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
InfuSystem Holdings Inc. (INFU) Business Model
About InfuSystem Holdings Inc.
Provides durable medical equipment and billing services.
The company generates revenue by supplying durable medical equipment, particularly ambulatory infusion pumps, and offering third-party billing services for healthcare providers. By partnering with oncologists and healthcare facilities, InfuSystem enhances patient care while managing the logistical and financial aspects of complex medical treatments.
InfuSystem operates in both the United States and Canada, serving key sectors such as oncology, surgery centers, and home healthcare. The company's focus on innovative solutions and operational efficiencies positions it as a vital player in the intersection of healthcare delivery and medical technology.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
502
CEO
Mr. Richard Armand DiIorio
Country
United States
IPO Year
2007
Website
www.infusystem.comInfuSystem Holdings Inc. (INFU) Latest News & Analysis
InfuSystem Holdings, Inc. will discuss its Q4 and full year 2024 financial results in a conference call on March 4, 2025, at 9:00 AM ET. Key executives will participate in the call.
The conference call will provide insights into InfuSystem's financial performance, guiding investors on growth potential, operational efficiency, and future outlook.
InfuSystem Announces Operational and Financial Results for Fourth Quarter and Full Year 2024
23 days agoInfuSystem has released its operational and financial results for Q4 and the full year 2024.
InfuSystem's operational and financial results will impact investor confidence, influence stock performance, and provide insights into the company's growth and profitability trends.
InfuSystems Holdings, Inc. (INFU) reported quarterly earnings of $0.04 per share, missing estimates of $0.08. This is an improvement from break-even earnings a year prior.
InfuSystems' earnings miss signals potential operational issues, possibly affecting stock performance and investor confidence in future growth.
InfuSystem to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
1 month agoInfuSystem will release its Fourth Quarter and Full Year 2024 financial results on March 4, 2025.
InfuSystem's upcoming financial results announcement could impact stock performance, investor sentiment, and market expectations, influencing investment decisions and valuations.
InfuSystem Set For Strong Year
1 month agoInfuSystem Holdings reported 11% YoY revenue growth and a 2.8% EBITDA margin increase in 3Q24, driven by partnerships with Smith+Nephew, SMTI, and Dignitana for FY25 growth.
InfuSystem's strong revenue growth and improved margins signal operational efficiency and profitability, bolstered by strategic partnerships that enhance future earnings potential.
InfuSystem will present at the Sidoti Small Cap Conference on December 4, 2024.
InfuSystem's presentation at a key investment conference can attract investor interest, potentially impacting stock performance and market perception.
Frequently Asked Questions About INFU Stock
What is InfuSystem Holdings Inc.'s (INFU) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, InfuSystem Holdings Inc. (INFU) has a median price target of $14.50. The highest price target is $15.00 and the lowest is $12.50.
Is INFU stock a good investment in 2025?
According to current analyst ratings, INFU has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INFU stock?
Wall Street analysts predict INFU stock could reach $14.50 in the next 12 months. This represents a 140.1% increase from the current price of $6.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is InfuSystem Holdings Inc.'s business model?
The company generates revenue by supplying durable medical equipment, particularly ambulatory infusion pumps, and offering third-party billing services for healthcare providers. By partnering with oncologists and healthcare facilities, InfuSystem enhances patient care while managing the logistical and financial aspects of complex medical treatments.
What is the highest forecasted price for INFU InfuSystem Holdings Inc.?
The highest price target for INFU is $15.00 from at , which represents a 148.3% increase from the current price of $6.04.
What is the lowest forecasted price for INFU InfuSystem Holdings Inc.?
The lowest price target for INFU is $12.50 from at , which represents a 107.0% increase from the current price of $6.04.
What is the overall INFU consensus from analysts for InfuSystem Holdings Inc.?
The overall analyst consensus for INFU is bullish. Out of 2 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $14.50.
How accurate are INFU stock price projections?
Stock price projections, including those for InfuSystem Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
